辛伐他丁联合灯盏细辛治疗ACS患者对C-反应蛋白水平的影响

目的探讨辛伐他丁联合灯盏细辛治疗急性冠状动脉综合征（ACS）患者对C反应蛋白（hs-CRP）水平的影响。方法抽取我院于2009年3月-2012年10月期间收治的96例急性冠状动脉综合征患者,将其随机分为对照组和观察组,每组48例。对照组患者给予常规药物治疗,包括阿司匹林、低分子肝素皮下注射、抗凝、抗心绞痛药物等,研究组则在对照组的基础上加用辛伐他丁20mg和静脉点滴灯盏细辛30 mL,1次/d,两组的疗程均为3个月。对比分析两组患者治疗前后的高敏C反应蛋白（hs-CRP）水平的变化情况以及死亡、心血管事件、不良反应的发生率。结果两组患者的hs-CRP水平较治疗前均明显降低,观察组则下降更为显著,从死亡和心血管事件的发生情况看,治疗组的发生率明显低于对照组,组间比较差异有统计学意义（P0.05）。结论辛伐他丁联合灯盏细辛治疗ACS患者能够显著降低hs-CRP水平,对稳定粥样斑块、减少严重心血管事件的发生有着重要意义,值得在临床上推广应用。

The impact of C -reactive protein in patients with ACS levels impastation therapy combined fleabane

[ Objective ] To investigate impastation combined fleabane acute coronary syndrome （ACS） patients with reactive protein （hs-CRP） levels of C. [ Methods ] I extracted the hospital in March 2009 -2012 admitted 96 cases during October in patients with acute coronary syndrome were randomly divided into control group and observation group, 48 cases in each group. The control group of patients treated with conventional medications, including aspirin, subcutaneous low molecular weight heparin, anticoagulant, anti-angina drugs, study group on the basis of the control group on the use of impastation 20mg and intravenous fleabane 30 mL, one day once, the two groups are 3 months of treatment. Comparative analysis of two groups of patients before and after treatment of high-sensitivity C-reactive protein （hs-CRP） levels and changes in mortality, the incidence of cardiovascular events, adverse reactions. [ Results ] The two groups of patients hs-CRP levels were significantly lower compared with the treatment, the observation group decreased more significantly , from the occurrence of death and cardiovascular events in perspective, the incidence of treatment group was significantly lower than the control group, the comparison between groups the difference was statistically significant （P〈0.05）; adverse reaction from the situation, were no serious adverse reaction , no statistically significant difference between groups（P〉0.05）. [ Conclusion ] The combined impastation therapy in patients with ACS fleabane can significantly reduce hs-CRP levels, to stabilize plaque and reduce the incidence of serious cardiovascular events of great significance, worthy of clinical application.